MET and intrahepatic cholangiocarcinoma: Mesenchymal epithelial transition(MET)encodes a receptor tyrosine kinase and that is activated by binding of its ligand, hepatocyte growth factor (HGF).4 Dysregulation of the MET pathway involves amplification, fusion, overexpression, and mutation.5 Several studies have indicated MET overexpression in 11%–43% of intrahepatic cholangiocarcinoma (IHCC) and 16%–80% in extrahepatic cholangiocarcinoma (EHCC).